For citation purposes: Wong SY, Hann HW. Hepatitis B-related hepatocellular carcinoma. OA Hepatology 2013 Dec 22;1(1):7.

Critical review

 
Liver Cancer

Hepatitis B-related hepatocellular carcinoma

SY Wong, HW Hann,
 

Authors affiliations

(1) Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

(2) Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

* Corresponding author Email: hie-won.hann@jefferson.edu

Abstract

Introduction

Hepatocellular carcinoma is one of the most deadly cancers in the world and has been found to be prevalent in hepatitis B virus endemic regions. The association of hepatitis B virus as a major factor in the development of hepatocellular carcinoma has been observed in the past. However, the mechanisms of hepatocarcinogenesis are not fully understood. Multiple studies have shown that treatment of hepatitis B with anti-viral therapy has led to the decreased incidence of hepatocellular carcinoma. More emerging data suggest that anti-viral therapy may also have a role in preventing the recurrence of hepatocellular carcinoma. The aim of this critical review was to discuss hepatitis B-related hepatocellular carcinoma.

Conclusion

The incidence of hepatitis B virus worldwide has overall decreased due to these preventive measures. However, hepatocellular carcinoma continues to be very prevalent and deadly. With further developments in more effective anti-viral therapy and worldwide implementation of vaccination programmes, it may be possible that hepatitis B virus and its associated hepatocellular carcinoma will be eradicated in the near future.

Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)
Keywords